EditorialClinical and regulatory implications of the cardiac arrhythmia suppression trial☆
References (8)
- et al.
Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide
JACC
(1986) - et al.
The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio
Am Heart J
(1989) Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
N Engl J Med
(1989)- et al.
Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy
N Engl J Med
(1988)
There are more references available in the full text version of this article.
Cited by (30)
PETER RUSSELL KOWEY, MD: A conversation with the editor
2014, American Journal of CardiologyImpact of managed care on the treatment of atrial fibrillation
1998, American Journal of CardiologyAtrial fibrillation: New management strategies
1993, Current Problems in CardiologyEvolutionary paths in arrhythmia management: Influences of substrate, studies, and seismology
1993, American Heart Journal
- ☆
The authors are members of the Cardiovascular and Renal Drugs Advisory Board to the Food and Drug Administration.
Copyright © 1990 Published by Elsevier Inc.